What’s Behind the 85% Surge in Aptevo Therapeutics Stock (APVO) Today?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 18 2025
0mins
Source: TipRanks
Investment Surge: Aptevo Therapeutics (APVO) stock experienced significant gains after Point72 Asset Management, led by billionaire Steven Cohen, acquired a 9.1% stake in the company, purchasing 299,944 shares.
Clinical Trial Success: The interest from Point72 follows Aptevo's recent announcement of a 100% remission rate in a clinical trial for its acute myeloid leukemia treatment, contributing to an 83.69% increase in pre-market trading despite a year-to-date decline of 98.35%.
Analyst Views on APVO
About APVO
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
